

Form Approved OMB No. 0920-0666 Exp. Date: 12/31/2027 www.cdc.gov/nhsn


Hemovigilance Module Adverse Reaction Delayed Hemolytic Transfusion Reaction

*Required for saving

*Facility ID#:	NHSN Adverse Reaction #:						
Patient Informatio	n						
*Patient ID: *Date of Birth:/							
*Sex: M F							
Social Security #:	Secondary ID:	Medic	Medicare #:				
Last Name:	First Name:	Middle Name:					
Ethnicity (Specify):	☐ Hispanic or Latino ☐ Not Hispanic or Latino		Declined to respond				
Race (Select all that apply):	☐American Indian or ☐Asian Alaska Native ☐Native Hawaiian or ☐White Pacific Islander	American Unknown	☐ Middle Eastern or North African ☐ Declined to respond				
Preferred Language (ded: Yes No lined to Respond Unknown					
*Blood Group: A- A+ B- B+ AB- AB- O- O+ Blood type not done Transitional ABO / Rh + Transitional ABO / Rh - Transitional ABO / Transitional Rh Group A/Transitional Group B/Transitional Rh Group O/Transitional Rh Group AB/Transitional Rh							
Patient Medical Hi	story						
List the patient's admitting diagnosis. (Use ICD-10 Diagnostic codes/descriptions)							
Code:	Description:						
Code:	Description:						
Code:							
List the patient's ur	nderlying indication for transfusion. (Use IC	D-10 Diagnostic cod	es/descriptions)				
Code:	Description:						
Code:	Description:						
Code:							
•	omorbid conditions at the time of the transfer- -10 Diagnostic codes/descriptions)	usion related to the a	dverse UNKNOWN				
Code:	Description:						
Code:	Description:						
Code:	Description:						

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). CDC 57.309 Rev. 3, v9.2

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666).





	nedical procedure including past procedures and procedures to be nt hospital or outpatient stay. (Use ICD-10 Procedure	☐ UNKNOWN					
Code:	Description:						
Code:	Description:						
Code:	Description:						
Additional Information							
Transfusion History							
Has the patient received a	previous transfusion?	IKNOWN					
Blood Product:							
Date of Transfusion:	// UNKNOWN						
Was the patient's advers	e reaction transfusion-related?						
If yes, provide informatio	n about the transfusion adverse reaction.						
Type of transfusion adve	rse reaction:	R 🗌 FNHTR					
☐ HTR ☐ TTI	☐ PTP ☐ TACO ☐ TAD ☐ TA-GVHD ☐ TRALI	UNKNOWN					
☐ OTHER Spec	fy						
Reaction Details							
*Date reaction occurred:	// *Time reaction occurred: :	unknown					
*Facility location where pat	ent was transfused:						
Is this reaction associated wit	h an incident?						
Investigation Results (O	nly answer questions listed under the selected reaction type.)						
	sfusion reaction (DHTR)						
	Non-immune (specify)						
*Case Definition							
Check the following that	occurred between 24 hours and 28 days after cessation of transfu	ısion:					
☐ Positive direct antigle							
_	blood cell alloantibody in recipient serum						
•	vith alloantibody present on the transfused red blood cells						
	st-transfusion hemoglobin level or rapid fall in hemoglobin back to pre-t	ransfusion levels					
Otherwise unexplained appearance of spherocytes							
Check all that apply:	,						
☐ Incomplete laboratory evidence							
☐ DHTR is suspected, but reported symptoms, test results, and/or available information are not sufficient							
Other signs and symptoms: (c							
Generalized:	• • • • • • • • • • • • • • • • • • • •	ea/vomiting					
Cardiovascular:	☐ Blood pressure decrease ☐ Shock	-					
	☐ Edema ☐ Flushing ☐ Jaund	dice					
Cutaneous:	<u> </u>						
Llamah saia/Llamarrhaga	<u> </u>	ıria (hives)					
Hemolysis/Hemorrhage:		oglobinemia					



Form Approved OMB No. 0920-0666 Exp. Date: 12/31/2027 www.cdc.gov/nhsn

Hematuria ☐ Hemoglobinuria Renal: ☐ Bilateral infiltrates on chest x-ray ☐ Bronchospasm ☐ Cough Respiratory: ☐ Hypoxemia ☐ Shortness of breath Other: (specify) *Severity Did the patient receive or experience any of the following? ☐ No treatment required Symptomatic treatment only ☐ Hospitalization, inlcuding prolonged hospitalization Life-threatening reaction ☐ Congenital anomaly or birth defect(s) of the fetus ☐ Disability and/or incapacitation Other medically important conditions ☐ Death ☐ Unknown or not stated *Imputability Which best describes the relationship between the transfusion and the reaction? ☐ No other explanation for symptoms or newly-identified antibody is present. An alternate explanation for symptoms or newly-identified antibody is present, but transfusion is the most likely cause. Other explanations for symptoms or newly-identified antibody are more likely, but transfusion cannot be ruled out. Evidence is clearly in favor of a cause other than the transfusion, but transfusion cannot be excluded. ☐ There is conclusive evidence beyond reasonable doubt of a cause other than the transfusion. The relationship between the adverse reaction and the transfusion is unknown or not stated. Did the transfusion occur at your facility? ☐ YES \square NO **Module-generated Designations** NOTE: Designations for case definition, severity, and imputability will be automatically assigned in the NHSN application based on responses in the corresponding investigation results section above. *Do you agree with the case definition designation? ☐ YES ^Please indicate your designation *Do you agree with the severity designation? ☐ YES □ио ^Please indicate your designation □ YES \square NO *Do you agree with the imputability designation? ^Please indicate your designation **Patient Treatment** Did the patient receive treatment for the transfusion reaction? ☐ YES \square NO If yes, select treatment(s): ☐ Medication (Select the type of medication) ☐ Antipyretics ☐ Antihistamines ☐ Inotropes/Vasopressors ☐ Bronchodilator Diuretics ☐ Intravenous Immunoglobulin ☐ Intravenous steroids ☐ Corticosteroids Antibiotics Antithymocyte globulin Cyclosporin ☐ Other ☐ Volume resuscitation (Intravenous colloids or crystalloids) Respiratory support (Select the type of support) Mechanical ventilation ■ Noninvasive ventilation Oxygen



Form Approved OMB No. 0920-0666 Exp. Date: 12/31/2027 www.cdc.gov/nhsn

☐ Renal replacement therapy (Select the type of therapy) ☐ Hemodialysis ☐ Peritoneal ☐ Continuous Veno-Venous Hemofiltration												
☐ Phlebotomy ☐ Other Specify:												
Outcome												
*Outcome: Death Major or long-term sequelae Minor or no sequelae Not determined												
Date of Death:/												
*If recipient died, relationship of transfusion to death:												
☐ Definite ☐ Probable ☐ Possible ☐ Doubtful ☐ Ruled Out ☐ Not determined												
	of death:											
vvas an	autopsy performed?	☐ Yes	☐ No	1								
*Was a partic		din (i.a. rosn	neibl	o for) the a	dvorso							
*Was a particular unit implicated in (i.e., responsible for) the adverse Pes No N/A reaction?												
Transfusion		Amount		number iired for	*Unit				Implic			
Start and End	*Component code transfused at Infec		Infect	expiration		*Blood group			ated			
Date/Time (check system used) reaction onset TRALI) Date/Time of unit Unit?												
^IMPLICATED												
//	☐ ISBT-128	☐ Entire unit			, ,	□ A-	□ A+ [□ B-				
:	☐ Codabar	Partial unit			/			_	Y			
/						□B+		□ AB+				
:					::	0-	O+ [□ N/A				
/	☐ ISBT-128	☐ Entire unit										
:	☐ Codabar	☐ Partial unit			//	□ A-	□ A+ [☐ B-	N			
		mL				□В+	☐ AB-	☐ AB+				
:					::	O-	O+ [□ N/A				
Custom Field	ds											
Label				Label								
							/	/				
Comments												